Hepatitis C Main Section
FDA-approved Monotherapies
FDA-approved Combination Therapies
Intron A
Roferon

Infergen
Pegasys
PEG-Intron
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Link to Hepatitis C Main Section

HCV - Hepatocellular Carcinoma

Human Genetic Variation May Protect Against HCV-related Liver Disease Progression - 1/04/08

Diabetes Is a Risk Factor for
Liver Cancer Recurrence after Surgery in Patients with Viral Hepatitis    - 7/13/07

New Drug for Treatment of Liver Cancer    - 6/12/07

Colchicine Delays the Development of Hepatocellular Carcinoma in Patients with Chronic Viral Hepatitis 10/13/06

HCV Core Protein Linked to Immune Evasion in Liver Cells  10/06/06

Mutation Patterns and Genotypes Associated with Hepatocellular Carcinoma in HBV/HCV Coinfected Patients   - 9/01/06

Long-term Effect of Interferon/Ribavirin on Incidence of Hepatocellular Carcinoma - 8/15/06

HCC
and Non-Liver Cancers in People with Cirrhosis - 6/23/06

New Compound May Protect Against Liver Cancer - 2/28/06

Natural Course of Hepatitis C Virus-infected Patients with Normal ALT and the Effect of Interferon Therapy on Hepatocellular Carcinoma in Those with Elevated ALT- 10/21/05